Further insights into the interplay between JAK1 selectivity and infection risk are provided by real-life data on the employment of a novel JAK2-selective drug, fedratinib, used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis. Here, JAK2 is linked to myelofibrosis.